Qelbree
| Chemical Name | viloxazine |
| Dosage Form | Extended-release capsule (oral; 100 mg, 150 mg, 200 mg) |
| Drug Class | Selective norepinephrine reuptake inhibitors |
| System | Nervous |
| Company | Supernus Pharmaceuticals |
| Approval Year | 2021 |
Indication
- For the treatment of attention deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older.